Trajenta Duo 2.5/1000 Tablet

Composition of Trajenta Duo 2.5/1000 Tablet

Trajenta Duo 2.5/1000 Tablet contains Linagliptin 2.5 mg + Metformin hydrochloride 1000 mg (prolonged/extended-release may vary by pack; confirm pack label). It belongs to the DPP-4 inhibitor + Biguanide class of medicines.

Uses of Trajenta Duo 2.5/1000 Tablet

Type 2 diabetes mellitus (as an adjunct to diet and exercise) to improve glycaemic control in adults when metformin alone is inadequate or when already treated with linagliptin and metformin.

Key benefits

• Lowers fasting and post-meal blood glucose
• Improves HbA1c control
• Low risk of hypoglycaemia when not combined with insulin/secretagogues
• Weight-neutral to modest weight benefit (metformin)
• Convenient combination therapy to reduce pill burden

How Trajenta Duo 2.5/1000 Tablet works

Linagliptin is a DPP-4 inhibitor that increases incretin levels, leading to glucose-dependent insulin release and reduced glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption and improves insulin sensitivity, lowering blood glucose without causing significant hypoglycaemia when used alone.

How to take Trajenta Duo 2.5/1000 Tablet

Oral tablet. Take exactly as prescribed, usually twice daily with meals (or as directed) to reduce stomach upset. Swallow whole with water; do not crush/chew if the pack is extended-release; follow label instructions. Monitor blood glucose regularly.

Take it exactly as your doctor prescribed. Do not change the dose or stop early on your own.

Missed dose and overdose

If you miss a dose

Take the missed dose of Trajenta Duo 2.5/1000 as soon as you remember. If it is almost time for the next dose, skip the missed one and carry on with the usual schedule. Do not take two doses together to make up for a missed dose.

If you take too much

Taking more Trajenta Duo 2.5/1000 than prescribed can be harmful. If you suspect an overdose, contact a doctor or go to the nearest emergency department at once, and carry the pack or strip with you. In India the emergency number is 112.

Side effects of Trajenta Duo 2.5/1000 Tablet

Most side effects of Trajenta Duo 2.5/1000 are mild and settle as the body adjusts. Reported side effects include:

• Nausea
• vomiting
• diarrhoea
• abdominal pain
• loss of appetite
• metallic taste
• headache
• nasopharyngitis
• cough
• dizziness
• hypoglycaemia (more likely with insulin/sulfonylureas)
• vitamin B12 deficiency (long-term)

Stop the medicine and seek help immediately for a rash, swelling of the face or lips, wheezing or difficulty breathing. Tell your doctor about any side effect that persists or worries you.

Safety advice for Trajenta Duo 2.5/1000 Tablet

Warnings and precautions

Risk of lactic acidosis with metformin (rare but serious): higher risk in kidney impairment, dehydration, severe infection, shock, liver disease, heavy alcohol use, or hypoxia/heart failure—seek urgent care for fast breathing, severe weakness, abdominal pain, or drowsiness. Assess renal function before starting and periodically; dose adjustments/avoid in significant renal impairment as per prescribing info. Temporarily stop metformin around iodinated contrast procedures and major surgery as advised. Pancreatitis and severe joint pain have been reported with DPP-4 inhibitors—stop and consult doctor if severe abdominal pain occurs. Use caution in elderly, undernourished, or those with alcohol use; monitor B12 with long-term use.

Interactions with other medicines

Iodinated contrast media, alcohol, carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide), cimetidine (may increase metformin levels), rifampicin (may reduce linagliptin effect), strong P-gp/CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital, rifampicin, St John’s wort), insulin and sulfonylureas (increased hypoglycaemia risk)

How to store Trajenta Duo 2.5/1000 Tablet

Store below 25°C in a dry place, protected from moisture and light. Keep in original blister pack and out of reach of children.

Manufacturer and class

Manufacturer:

Boehringer Ingelheim India Pvt Ltd

Therapeutic class:

Antidiabetic

Drug class:

DPP-4 inhibitor + Biguanide